As Vice President Research at Hookipa, Dr. Klaus Orlinger is responsible for generation and characterization of prophylactic and therapeutic vaccines/immunotherapy candidates. He developed Hookipa’s cytomegalovirus vaccine candidate, HB-101. Klaus brings more than 10 years of experience in the field of virology, including involvement in the development and life cycle management of various vaccines and candidates for infectious diseases. Prior to joining Hookipa, he led a research team in the molecular vaccines department at Baxter BioScience. Klaus holds an MSc and PhD in genetics/microbiology from the University of Vienna and the Medical University of Vienna, respectively.